Vimarsana
Biggest News Aggregation in the World

Zarit Burden News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Zarit Burden. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Zarit Burden Today - Breaking & Trending Today

"The Context of Caregiving in Heart Failure: A Dyadic, Mixed Methods An" by Martha Abshire Saylor, Lyndsay Degroot et al. - Vimarsana News

"The Context of Caregiving in Heart Failure: A Dyadic, Mixed Methods An" by Martha Abshire Saylor, Lyndsay Degroot et al.

Background Caregiving for persons with heart failure (HF) varies based on the individual, family, and home contexts of the dyad, yet the dyadic context of HF caregiving is poorly understood. Objective The aim of this study was to explore dyadic perspectives on the context of caregiving for persons with HF. Methods Family caregivers and persons with HF completed surveys and semistructured interviews. Investigators also photographed caregiving areas to complement home environment data. Descriptive qualitative analysis resulted in 7 contextual domains, and each domain was rated as strength, need,...

Source: uow.edu.au
BioArctic: New lecanemab-data presented at the AD/PD™ 2023 conference - Vimarsana News

BioArctic: New lecanemab-data presented at the AD/PD™ 2023 conference

STOCKHOLM, April 3, 2023 /PRNewswire/ -- BioArctic AB and its partner Eisai has presented new findings on lecanemab , an anti-amyloid beta protofibril antibody for the treatment of Alzheimer's... | April 3, 2023

BioArctic: New lecanemab-data presented at the AD/PD 2023 conference - Vimarsana News

BioArctic: New lecanemab-data presented at the AD/PD 2023 conference

STOCKHOLM, April 3, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and its partner Eisai has presented new findings on lecanemab (generic name, U.S. brand name: LEQEMBI)

BioArctic: New lecanemab-data presented at the AD/PD™ 2023 conference (1) - Vimarsana News

BioArctic: New lecanemab-data presented at the AD/PD™ 2023 conference (1)

STOCKHOLM, April 3, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and its partner...

EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING - Vimarsana News

EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...